Skip to main content

Table 2 Sub-cohort demographics

From: Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods

  Total sample CN MCI AD p value
N (%) 50 36 (72) 8 (16) 6 (12)  
PET-Aβ+ (%) 23 (46) 12 (35) 5 (71) 6 (100) 0.0029
Gender male, N (%) 21 (42) 14 (39) 3 (38) 4 (67) 0.54
Mean age, years (SD) 72.8 (5.8) 73.1 (5.6) 73.5 (7.3) 70.5 (5.3) 0.42
APOE ε4 carriage, N (%) 16 (32) 9 (25) 4 (50) 4 (50) 0.26
Median MMSE, (MAD) 28 (3) 29 (1.5) 27 (2.2) 23.5 (4.4) 0.0019
Median CDR score, (MAD) 0 (0) 0 (0) 0.5 (0) 1 (0.4) < 0.0001
  1. Abbreviations: N number, CN cognitively normal, MCI mild cognitive impairment, AD Alzheimer’s disease, APOE ε4 Apolipoprotein E epsilon 4 allele, APOE ε4 Carriage, N (%) number of participants with at least one APOE ε4 allele, MMSE Mini-Mental State Examination, CDR Clinical Dementia Rating, IQR inter-quartile range, MAD maximum absolute deviation, PET-Aβ Positron Emission Tomography Amyloid Beta. p value determined by t-test (age), chi-square analyses (PET-Aβ status, APOE ε4, and gender) and Kruskal-Wallis tests (CDR score and MMSE)